Biogen Idec and Belgian biopharmaceutical Co UCB SA discontinued the Phase II clinical trial of CDB323 treatment for relapsing-remitting Multiple Sclerosis today, saying no clinically relevant benefit was seen for patients after six months in a trial of CDB323 compared with placebo...
http://www.nasdaq.com/aspx/stock-mar...osis-treatment